Drug resistance and gene amplification potential regulated by transforming growth factor beta 1 gene expression

A Huang1, H Jin, J A Wright

  • 1Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg, Canada.

Cancer Research
|April 15, 1995
PubMed

Insights

Transforming growth factor beta 1 (TGF-beta 1) overexpression reduces cancer cell sensitivity to PALA chemotherapy. This suggests TGF-beta 1 promotes drug resistance and tumor progression by decreasing genetic stability.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Transforming growth factor beta 1 (TGF-beta 1) is crucial for mammalian cell functions.
  • Aberrant TGF-beta 1 expression is linked to malignant progression.
  • N-(phosphonacetyl)-L-aspartate (PALA) is a chemotherapy drug targeting the CAD gene.

Purpose of the Study:

  • To investigate the role of TGF-beta 1 in drug resistance and genetic stability.
  • To determine if TGF-beta 1 affects sensitivity to PALA chemotherapy.
  • To explore the link between TGF-beta 1 and CAD gene amplification.

Main Methods:

  • Transfected mouse 10T1/2 cells with TGF-beta 1.
  • Utilized a zinc sulfate-inducible metallothionein promoter to control TGF-beta 1 expression.
  • Assessed PALA sensitivity and resistance rates.
  • Performed Southern blot analysis to detect CAD gene amplification.

Main Results:

  • TGF-beta 1 overexpression reduced sensitivity to PALA's cytotoxic effects.
  • Elevated TGF-beta 1 levels correlated with significantly reduced PALA sensitivity.
  • Higher TGF-beta 1 expression led to increased rates of PALA resistance and CAD gene amplification.
  • TGF-beta 1 overexpression decreased genetic stability in 10T1/2 cells.

Conclusions:

  • Aberrant TGF-beta 1 expression promotes drug resistance and tumor progression.
  • TGF-beta 1 alterations decrease genetic stability, increasing gene amplification potential.
  • TGF-beta 1 plays a novel role in malignancy and chemotherapy resistance mechanisms.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...